IN8bio Inc

NAS:INAB (USA)   Ordinary Shares
$ 0.30 -0.0138 (-4.45%) 11:08 PM EST
At Loss
P/B:
1.65
Market Cap:
$ 21.47M
Enterprise V:
$ 23.94M
Volume:
292.24K
Avg Vol (2M):
1.47M
Trade In:
Volume:
292.24K
At Loss
Avg Vol (2M):
1.47M

Business Description

IN8bio Inc
NAICS : 325412 SIC : 2834
ISIN : US45674E1091

Share Class Description:

INAB: Ordinary Shares
Description
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.
Name Current Vs Industry Vs History
Cash-To-Debt 0.73
Equity-to-Asset 0.54
Debt-to-Equity 0.64
Debt-to-EBITDA -0.19
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 1/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 28.57
9-Day RSI 40.54
14-Day RSI 45
6-1 Month Momentum % -69.31
12-1 Month Momentum % -55.07

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 1.84
Quick Ratio 1.84
Cash Ratio 1.1

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -30.6
Shareholder Yield % -62.21
Name Current Vs Industry Vs History
ROE % -193.35
ROA % -128.6
ROIC % -259.19
ROC (Joel Greenblatt) % -337.24
ROCE % -154.03

GF Value Rank

Name Current Vs Industry Vs History
PB Ratio 1.65
Price-to-Tangible-Book 1.65
EV-to-EBIT -0.76
EV-to-EBITDA -0.83
EV-to-FCF -0.95
Earnings Yield (Greenblatt) % -131.58
FCF Yield % -117.37

Financials (Next Earnings Date:2025-03-14 Est.)

INAB's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:INAB

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

IN8bio Inc Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $)
EPS (TTM) ($) -0.75
Beta -0.06
Volatility % 102.1
14-Day RSI 45
14-Day ATR ($) 0.039014
20-Day SMA ($) 0.32179
12-1 Month Momentum % -55.07
52-Week Range ($) 0.217 - 2.48
Shares Outstanding (Mil) 72.48

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 1
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

IN8bio Inc Filings

Filing Date Document Date Form
No Filing Data

IN8bio Inc Stock Events

Financials Calendars
Event Date Price($)
No Event Data

IN8bio Inc Frequently Asked Questions

What is IN8bio Inc(INAB)'s stock price today?
The current price of INAB is $0.30. The 52 week high of INAB is $2.48 and 52 week low is $0.22.
When is next earnings date of IN8bio Inc(INAB)?
The next earnings date of IN8bio Inc(INAB) is 2025-03-14 Est..
Does IN8bio Inc(INAB) pay dividends? If so, how much?
IN8bio Inc(INAB) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1